Cost-Effectiveness and Budget Impact Analysis for Russian Federation of the fluvoxamine replacement in the treatment of recurrent depression of tricyclic antidepressants

Plavinski S. L.
MD¹

Davydov K.V.
PhD²

1 - North-West State Medical University named after I.I. Mechnikov, Saint-Petersburg, Russia
2 - Moscow Research Institute of Psychiatry

Tricyclic antidepressants (TCA) and selective serotonin reuptake inhibitors (SSRI) are the main drug classes used in the treatment of recurrent depressive disorder. The study analyzed cost-effectiveness and budget impact of replacement of TCA with SSRI fluvoxamin. It was found that when indirect costs (GDP loss due to lost workdays) is taken into account use of fluvoxamine dominated TCA by both effectiveness and costs. If indirect costs were ignored then increment cost-effectiveness ration (77,6 thou. RUR/ QALY gained) was well below «willingness to pay» threshold. If indirect costs were taken into account budget savings from replacing treatment with amitriptyline and clomipramine in 50% of cases amount to 3632 mln. RUR per year, if only clomipranime is replaced – 1695 mln. RUR per year.

fluvoxamine, amitriptyline, clomipramine, recurrent depressive disorder

1. Sex and depression in the National Comorbidity Survey. I: Lifetime prevalence, chronicity and recurrence / R. C. Kessler, K. A. McGonagle, M. Swartz et al. // J Affect Disord. – 1993. – Vol. 29, no. 2-3. – Pp. 85–96.

2. Trivedi, M. H. Measurement-based care for refractory depression: a clinical decision support model for clinical research and practice / M. H. Trivedi, E. J. Daly // Drug Alcohol Depend. – 2007. – Vol. 88 Suppl 2. – Pp. 61–71.

3. Retrospective observational study to estimate the duration of initial antidepressant treatment in patients with recurrent depressive disorder who demonstrated a suboptimal response to therapy – DIANA: Tech. rep. / A. Avedisova, A. Smulevich, G. Mazo, K. Otter: AstraZeneca, NIS REPORT SYNOPSIS, 2014.

4. Cost effectiveness of fluvoxamine in the treatment of recurrent depression in France / M. Nuijten, L. Hadjadjeba, C. Evans, J. van den Berg // Pharmacoeconomics. – 1998. – Vol. 14, no. 4. – Pp. 433–445.

5. Jonsson, B. What price depression? The cost of depression and the cost-effectiveness of pharmacological treatment / B. Jonsson, P. E. Bebbington // Br J Psychiatry. – 1994. – Vol. 164, no. 5. – Pp. 665–673.

6. The size and burden of mental disorders and other disorders of the brain in Europe 2010 / H. U. Wittchen, F. Jacobi, J. Rehm et al. // Eur Neuropsychopharmacol. – 2011. – Vol. 21, no. 9. – Pp. 655–679.

7. Depression prevalence and estimation of psychosocial parameters within adult population in city of Zagreb / S. Stojanovic-Spehar, S. Blazekovic-Milakovic, V. Amerl-Sakic et al. // Psychiatr Danub. – 2009. – Vol. 21, no. 4. – Pp. 497–507.

8. The estimated incidence of depressive disorder and its determinants in the Finnish ODIN sample / V. Lehtinen, B. Sohlman, T. Nummelin et al. // Soc Psychiatry Psychiatr Epidemiol. – 2005. – Vol. 40, no. 10. – Pp. 778–784.

9. Yagudina R., Kulikov A., Nguyen T. Place of threshold willingness-to-pay of Russia among those of other European countries and CIS countries // Pharmacoeconomica. – 2011. – Vol. 4, № 1. – Pp. 7–12.